Skip to main content

Dexamethasone Dose for COVID-19 in a Large U.S. Hospital Network From April 2020 to May 2023

Basic Details
Date
Type
Publication
Description

While potential harm from high doses of systemic dexamethasone for clinical management of COVID-19 is an important concern, little is known about real world dexamethasone dosing in patients hospitalized with COVID-19 in the United States. We conducted a descriptive study to assess dexamethasone daily dose in adults with COVID-19 in a large US hospital network, overall and by respiratory support requirements, extracted using semi-structured nursing notes.

Materials

Pharmacoepidemiol Drug Saf. 2024 Oct 17. doi.org/10.1002/pds.70018.

Related Assessment(s)
Presentation: High Dose Dexamethasone for COVID-19 Not Common in a Large US Hospital Network
Publication: Validity of Inpatient Electronic Health Record-Based Measures of Oxygen-Related Therapy in the United States: Lessons Applicable for Studying COVID-19 Endpoints
Sentinel Methods Project: HCA COVID-19 Activities: Monitoring of Critical Drugs and Assessment of Natural History of Disease
Author(s)

Marie C. Bradley, Ashish Rai, Austin Cosgrove, Silvia Perez-Vilar, Candace Fuller, Edward Rosen, Efe Eworuke, Laura E. McLean, Jeffrey S. Guy, Russell E. Poland, Kenneth E. Sands, Gerald J. Dal Pan

Corresponding Author

Marie C. Bradley; Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration

Email: marie.bradley@fda.hhs.gov